Evidence map›Paper›PMID 36193499›Full record

ArticleDisease markers2022

Haibo Li, Ghazaleh Behnammanesh, Zhenkai Wu, Rong Rong, Mengling You, Aman Shah Abdul Majid, Dan Ji

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Haibo LiEye Center of Xiangya Hospital and Hunan Key Laboratory of Ophthalmology, Central South University, Changsha, 410008 Hunan Province, China.
Ghazaleh BehnammaneshDepartment of Pharmacology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Zhenkai WuThe First People's Hospital of Changde, Changde City, 415000 Hunan Province, China.
Rong RongEye Center of Xiangya Hospital and Hunan Key Laboratory of Ophthalmology, Central South University, Changsha, 410008 Hunan Province, China.
Mengling YouEye Center of Xiangya Hospital and Hunan Key Laboratory of Ophthalmology, Central South University, Changsha, 410008 Hunan Province, China.
Aman Shah Abdul MajidDepartment of Pharmacology, Quest International University Perak, Ipoh, Malaysia.
Dan JiEye Center of Xiangya Hospital and Hunan Key Laboratory of Ophthalmology, Central South University, Changsha, 410008 Hunan Province, China.ORCID https://orcid.org/0000-0001-5901-3672
Central South University · CNQuest International University Perak · MYThe First People's Hospital of Changde · CNUniversiti Sains Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of low-cost and effective natural products for treating neuron degenerative diseases have proven to be safe and potentially effective.

Indexed as

Biological ProductsCrush InjuriesEchiumNeuroprotective AgentsOptic Nerve InjuriesAnimalsAntioxidantsCell SurvivalCytokinesDisease Models, AnimalEthanolGlutamic AcidMiceNF-kappa BOptic NervePlant ExtractsAntioxidantsBiological ProductsCytokinesEthanolGlutamic AcidNeuroprotective AgentsNF-kappa BPlant ExtractsReactive Oxygen Species

Identifiers

PMID36193499
PMCPMC9526585
OpenAlexW4296743011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.